Key Points
- Insider sale: Director Marcella Ruddy sold 10,000 shares on March 6 at an average price of $30, reducing her stake by 12.54% and leaving her with 69,747 shares (≈$2.09M); the transaction was filed with the SEC.
- Stock trading and metrics: NASDAQ:TECX opened at $34 and was down about 5.2%, with a market cap of $638.5M, a 50-day/200-day moving average of $22.05/$19.80, and a 12‑month range of $13.70–$36.03.
- Analyst and institutional view: Tectonic reported QEPS of -$1.03 (beating estimates), has a consensus rating of "Moderate Buy" with a $81.50 target, and large institutions like Millennium and Goldman significantly increased positions recently.
Tectonic Therapeutic, Inc. (NASDAQ:TECX - Get Free Report) insider Peter Mcnamara sold 6,262 shares of the business's stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $30.17, for a total transaction of $188,924.54. Following the sale, the insider owned 55,285 shares of the company's stock, valued at $1,667,948.45. This represents a 10.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Peter Mcnamara also recently made the following trade(s):
- On Wednesday, March 4th, Peter Mcnamara sold 1,650 shares of Tectonic Therapeutic stock. The shares were sold at an average price of $25.00, for a total transaction of $41,250.00.
- On Tuesday, March 3rd, Peter Mcnamara sold 1,649 shares of Tectonic Therapeutic stock. The shares were sold at an average price of $22.06, for a total transaction of $36,376.94.
Tectonic Therapeutic Price Performance
Shares of NASDAQ:TECX opened at $34.00 on Tuesday. The company's fifty day moving average price is $22.05 and its 200 day moving average price is $19.80. Tectonic Therapeutic, Inc. has a 12 month low of $13.70 and a 12 month high of $36.03. The firm has a market capitalization of $638.52 million, a P/E ratio of -8.40 and a beta of 3.75.
Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.03) earnings per share for the quarter, beating analysts' consensus estimates of ($1.11) by $0.08. On average, sell-side analysts anticipate that Tectonic Therapeutic, Inc. will post -8.31 EPS for the current year.
Hedge Funds Weigh In On Tectonic Therapeutic
Hedge funds and other institutional investors have recently bought and sold shares of the company. Police & Firemen s Retirement System of New Jersey acquired a new position in Tectonic Therapeutic in the 2nd quarter valued at $52,000. Caitong International Asset Management Co. Ltd raised its position in Tectonic Therapeutic by 451.6% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 3,966 shares of the company's stock worth $62,000 after buying an additional 3,247 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Tectonic Therapeutic by 26.7% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 3,750 shares of the company's stock worth $75,000 after acquiring an additional 791 shares during the period. Virtus Investment Advisers LLC boosted its holdings in shares of Tectonic Therapeutic by 18.3% in the second quarter. Virtus Investment Advisers LLC now owns 4,190 shares of the company's stock valued at $83,000 after acquiring an additional 649 shares in the last quarter. Finally, New York State Common Retirement Fund purchased a new stake in shares of Tectonic Therapeutic in the second quarter valued at about $99,000. 62.63% of the stock is currently owned by hedge funds and other institutional investors.
Key Stories Impacting Tectonic Therapeutic
Here are the key news stories impacting Tectonic Therapeutic this week:
- Positive Sentiment: Analysts maintain a constructive view — the consensus rating is "Moderate Buy" with a hefty consensus target (~$81.50) and multiple buy/strong-buy notes on the stock, which supports upside expectations. Analyst Coverage
- Positive Sentiment: Momentum/relative-strength is strong — coverage highlighting a 96 RS rating signals market leadership and technical strength that can attract momentum funds. RS Rating Article
- Positive Sentiment: Institutional buying has increased — recent filings show large purchases/position increases from Millennium, Goldman Sachs and others, indicating professional investor interest and providing a demand floor. Institutional Activity
- Neutral Sentiment: Leadership transition announced — the company named a new chair and announced an executive transition. Impact depends on the incoming chair’s strategic direction and how management communicates near-term priorities. Leadership Transition
- Negative Sentiment: Insider selling by Marcella Ruddy — sold 10,000 shares at ~$30 (reducing her stake ~12.5%). Large, disclosed insider sales are likely a primary reason for downward pressure on the stock today. Ruddy Sale
- Negative Sentiment: Insider selling by Peter McNamara — sold 6,262 shares at ~$30.17 (about a 10.2% reduction in his position), adding to selling flow and negative sentiment. Mcnamara SEC Filing
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on TECX. Truist Financial decreased their target price on Tectonic Therapeutic from $64.00 to $60.00 and set a "buy" rating for the company in a research report on Thursday, January 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tectonic Therapeutic in a research report on Thursday, January 22nd. Finally, Lifesci Capital raised Tectonic Therapeutic to a "strong-buy" rating in a report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $81.50.
View Our Latest Stock Analysis on TECX
Tectonic Therapeutic Company Profile
(
Get Free Report)
Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
